Reuters logo
U.S. FDA approves AstraZeneca's bladder cancer drug
May 1, 2017 / 5:09 PM / 7 months ago

U.S. FDA approves AstraZeneca's bladder cancer drug

May 1 (Reuters) - The U.S. Food and Drug Administration on Monday granted accelerated approval to AstraZeneca Plc’s immuno-oncology drug to treat a type of bladder cancer in patients whose disease progressed following chemotherapy.

As a condition of the accelerated approval, AstraZeneca is required to complete an ongoing clinical trial to confirm the clinical benefit of the drug, durvalumab. ( (Reporting by Divya Grover in Bengaluru; Editing by Supriya Kurane)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below